

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Mirxes Holding Company Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2629)

**VOLUNTARY UNDERTAKING
NOT TO SELL SHARES OF THE COMPANY
BY THE CO-FOUNDERS AND THE CORNERSTONE INVESTOR**

This announcement is made by Mirxes Holding Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to (i) the prospectus of the Company dated May 15, 2025 (the “**Prospectus**”); (ii) the allotment results announcement of the Company dated May 22, 2025 (the “**Announcement**”); and (iii) the announcement of the Company dated November 13, 2025, in relation to, among others, the lock-up undertakings (the “**Lock-Up Undertakings**”) given by the Company’s co-founders (the “**Co-Founder(s)**”) and cornerstone investor (the “**Cornerstone Investor**”) in respect of their respective shareholdings in the Company. Please refer to the Prospectus for further details on the Lock-Up Undertakings. Unless otherwise defined, terms used in this announcement shall have the same meaning as those defined in the Prospectus and the Announcement.

Such existing Lock-Up Undertakings in respect of the relevant shares of the Company (the “**Shares**”) held by the Co-Founders and the Cornerstone Investor will expire on February 23, 2026.

The Company is pleased to announce that each of the Co-Founders, namely Dr. Too Heng Phon (holder of 32,419,381 Shares), Dr. Zhou Lihan (controller of 18,660,556 Shares held through SLW Gene Limited) and Dr. Zou Ruiyang (controller of 17,860,556 Shares held through Accurate Gene Limited), as well as the Cornerstone Investor, Beijing Xunrui Enterprise Management Partnership (Limited Partnership) (holder of 16,649,200 Shares), has voluntarily given an undertaking to the Company (the “**Voluntary Undertakings**”) in relation to their respective shareholdings in the Company as particularized above (the “**Relevant Shares**”) following the expiry of the existing Lock-Up Periods.

The Voluntary Undertakings reflect the Co-Founders' and the Cornerstone Investor's strong confidence in the Company's long-term prospects, underlying business fundamentals and strategic direction, and demonstrate their commitment to remain long-term shareholders of the Company and to support its sustainable growth and value creation.

Pursuant to the Voluntary Undertakings, for a period of 12 months following February 23, 2026:

- (i) each Co-Founder has undertaken that he will not sell any of his Relevant Shares; and
- (ii) the Cornerstone Investor has undertaken that they will hold at least 80% of their Relevant Shares.

The Company believes that the Voluntary Undertakings by the Co-Founders and Cornerstone Investor also reflect their recognition of positive developments in the Company's business. This includes, but is not limited to, the Company's recently announced strategic initiatives relating to new mergers and acquisitions, the advancement of research and development across its pipeline (including multi-cancer early detection solutions) and expansion into emerging markets, as disclosed in the announcement in connection with the closing of the placing of new Shares by the Company dated February 5, 2026. The Company will continue to build upon these developments and pursue its long-term development objectives in alignment with the interests of its shareholders.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, February 11, 2026

As of the date of this announcement, the Board comprises (i) Dr. ZHOU Lihan and Dr. ZOU Ruiyang as executive Directors; (ii) Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da as non-executive Directors; and (iii) Dr. LAM Sin Lai Judy, Mr. FANG Xiao and Ms. MA Andrea Lo Ling as independent non-executive Directors.